Shaji Kumar

OK here it is. Finally. My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD Give comments. I’m willing to adjust it based on your insights. https://t.co/uP8RFXIKYU

#ASH25 congrats @szusmani @myelomaMD et al: EXCELLENT RedirecTT-1!! True hope for true EMD 👏 I agree with Ben & will add Consort from @NEJM - no attrition due to PD/death with off-the-shelf bsAb duo. Peri-CAR-T holding & bridging so hard in true EMD. Maybe we don’t need to! https://t.co/LqiXMLplPg https://t.co/ho06P2SZ2w

#IMS26 Plenary presentation for CERVINO demonstrates clear superiority of TCEs over SOC! 👏👏@PlasmaCellPete @myelomaMD et al. 12-mo PFS of 62.1% with Etentamig vs. 28.4% with control (Kd, SVd, EloPd) OS showing encouraging trend as well! Surely no more non TCE control arms https://t.co/uJfngfYOza

Heading to #IMS26 ! Going through all the amazing abstracts, A few things on my radar this year so far: — CERVINO: first phase 3 readout for a BCMA bispecific vs standard-of-care in triple-class exposed RRMM — PERSEUS at 6+ years — does the PFS advantage for quad induction hold up long-term, and is there finally an OS signal? — Two separate first-in-human reports of in vivo CAR-T generation — no apheresis, no lymphodepletion. If this works, it changes how we think about access to cellular therapy entirely. — CARTITUDE-2 5-year data on cilta-cel in earlier-line RRMM — EXCALIBER-RRMM: iberdomide's first phase President of IMS - Prof Phillip Moreau and his executive team, @myelomaMD @mvmateos @NoopurRajeMD @NikhilMunshiMD have put together an amazing meeting with 669 abstracts and many amazing talks ! I will be tweeting important practice changing abstract through rest of week; excited for busy week :) #Myeloma #HemOnc #IMS2026 #glasgow